

US Family Health Plan
Prior Authorization Request Form for
ustekinumab (**Stelara**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? **Call 1-877-880-7007**

Step 1 Please complete patient and physician information (please print):

Patient Name: _____	Physician Name: _____
Address: _____	Address: _____
Sponsor ID #: _____	Phone #: _____
Date of Birth: _____	Secure Fax #: _____

Step 2 Please complete clinical assessment:

1. Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?	<input type="checkbox"/> Yes Proceed to question 3	<input type="checkbox"/> No Proceed to question 2
2. Is the patient between the ages of 6 and 17 years old AND has a diagnosis of plaque psoriasis?	<input type="checkbox"/> Yes Proceed to question 9	<input type="checkbox"/> No Proceed to question 5
3. Has the patient had an inadequate response to Humira?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No Proceed to question 4
4. Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No STOP Coverage not approved
5. Does the patient have a contraindication to Humira (adalimumab)?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No STOP Coverage not approved
6. Is the patient 18 years of age or older?	<input type="checkbox"/> Yes Proceed to question 7	<input type="checkbox"/> No Proceed to question 8
7. What is the indication or diagnosis in this adult patient?	<div style="display: flex; flex-direction: column; gap: 5px;"><div><input type="checkbox"/> Active psoriatic arthritis (PsA) alone or in combination with methotrexate – Proceed to question 10</div><div><input type="checkbox"/> Moderately to severely active Crohn's disease (CD) – Proceed to question 10</div><div><input type="checkbox"/> Moderately to severely active plaque psoriasis who are candidates for phototherapy or systemic therapy – Proceed to question 10</div><div><input type="checkbox"/> Moderately to severely active ulcerative colitis (UC) – Proceed to question 10</div><div><input type="checkbox"/> Other indication or diagnosis – STOP: coverage not approved.</div></div>	
8. Is the patient 6 years of age or older?	<input type="checkbox"/> Yes Proceed to question 9	<input type="checkbox"/> No STOP Coverage not approved

USFHP Prior Authorization Request Form for
ustekinumab (**Stelara**)

9. What is the indication or diagnosis in this pediatric patient?

- ☐ Moderate to severe active **plaque psoriasis** who are candidates for phototherapy or systemic therapy – Proceed to question **10**
- ☐ Other indication or diagnosis – **STOP: coverage not approved.**

10. Has the patient had an inadequate response to non-biologic systemic therapy? For example: methotrexate, aminosalicylates [e.g. sulfasalazine, mesalamine], corticosteroids, immunosuppressants [e.g. azathioprine], etc.

☐ Yes
Proceed to question **11**

☐ No
STOP
Coverage not approved

11. Does the patient have evidence of a negative TB test result in the past 12 months (or TB is adequately managed)?

☐ Yes
Proceed to question **12**

☐ No
STOP
Coverage not approved

12. Will the patient be receiving other targeted immunomodulatory biologics with Stelara, including but not limited to the following: Actemra, Cimzia, Cosentyx, Enbrel, Humira, Ilumya, Kevzara, Kineret, Olumiant, Orencia, Otezla, Remicade, Rinvoq ER, Rituxan, Siliq, Simponi, Skyrizi, Taltz, Tremfya or Xeljanz/Xeljanz XR?

☐ Yes
STOP
Coverage not approved

☐ No
Sign and date below

Step
3

I certify the above is true to the best of my knowledge. Please sign and date:

Prescriber Signature

Date

[30 December 2020]